Clinical trials using MAF for hospitalized COVID-19 patients

Cov19-bl-1.jpg

US National Library of Medicine, NIH clinical trial

Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)

Dr001.jpg

Kazakhstan

The clinical trial using MAF capsules has started in Kazakhstan for the patients suffering with coronavirus aftereffects in February 2021.

Cov-green.jpg

Ukraine

Update on the clinical trial using MAF for hospitalized COVID-19 patients in Ukraine

1200x1200_M-Capsules_2bottles_1.jpg

Italy

The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.

800_aftereffect.jpg

Ukraine

The clinical trial using MAF capsules has started in Ukraine from the end of October for hospitalised patients with COVID-19.

Cov-man.jpg

Rationales of MAF as a therapeutic target for SARS-CoV-2

The fact that around 96% of patients recover from the infection

US01.jpg

Potential role of GcMAF

Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV

Free from

Wheat, soy, egg, rice, gluten, starch, sugar (excluding M-Lollies), hormones, antibiotics, preservatives, artificial sweeteners, artificial colours.

Easy to take

We have created 2 types of MAF products to cover many areas such as mouth, gut and skin.
 

Very unique MAF

We have developed our very own unique MAF (macrophage activating factor) using our patented method. MAF helps boost the immune system by activating macrophages without any side effects.

Produced in GMP Certified factory in Japan

MAF Series products are produced in our Saisei Mirai GMP Certified factory (Certification No. 26518) in Moriguchi, Osaka, certified by the Ministry of Health, Labor and Welfare of Japan.

NEWS

Saisei Pharma plans clinical study of oral MAF in COVID-19 patients

Clinical trial to evaluate oral MAF, macrophage activating factor, in the prevention of the COVID-19 associated cytokine storm and the role of macrophages as a front-line innate immunity defense is announced.
A cytokine storm is a type of severe immune overreaction that could result from the novel coronavirus infection and may contribute to acute respiratory disease which has life-threatening complications in patients with COVID-19.

“Our innate immunity can fight off pathogens without causing inflammation and associated respiratory deterioration.”

Our Press Release featured on the following sites:
3rd Generation GcMAF was developed by Saisei Pharma for which we hold patents. There are fake GcMAF products sold online in Australia by a company which is registered in Hong Kong. Please be aware that 3rd Generation GcMAF products are only produced by Saisei Pharma. Any other products from other companies are fake products.

We were informed that a company calling themselves “Japan Health” with the websites bio-japan.net and japan-health.net is claiming to be selling our products. This seller is unverified and we have never sold our products to them. Especially our Second Generation GcMAF vials are only sold from Saisei Mirai Clinics in Japan and we do not authorize anyone to re-sell them unless they are registered as a Medical Doctor with us and prescribing them to patients. We recommend ordering GcMAF only from a trusted and reliable source. If you are unsure of the source, please contact us to confirm.

Saisei Mirai Group

Saisei Mirai Group

We have partnered with 5 domestic clinics in Japan which are based on Saisei Mirai Medical Corporation, bio-venture companies, pharmacies, and universities and medical institutions in Japan and overseas, and have started providing advanced medical care worldwide.

Wholesale Distributor

Wholesale Distributors

Introducing overseas distributors that sell our products.
Momadeus.com

Sweden
shipping within EU countries

MACOTİZM

SPORTİF TESİSLER İŞLETMECİLİĞİ VE DANIŞMANLIK TİC LTD ŞTİ - Turkey

MACMAF

MacMAF is a company owned by macotism

MedInc

Kazakhstan
Uzbekistan, Kyrgyzstan

error: Content is protected !!